Well said, kkllfla. I saw them try the same pattern with ISRG when in it's infancy. It a lot of shorts lost their shorts as the stock continues huge upside moves each quarterly earnings. NVDQ, if it can develop its application base could very well have a similar market and earnings trajectory.
Andersongordon and kklllfla
Could not agree more with your assessments of this company's technology. I spent a couple of hours this summer listening to their investor day presentations. Their equipment is sure to become a best practice part of a growing number of different operations. It is no coincidence that the current slide in pps has been accompanied by a steady increase in short sales. The recent press release on the purchase of a Pinpoint device by Mamonides Hospital also tells an excellent story.
Not sure what informed short thesis is here - unlike early stage biotech which hemmorages cash and often has binary outcomes based on unpredictable clinical trials - here you dont have either of those concerns - you actually have growth of an installed base - which may take longer than some would like, but OK. I say "informed" b/c we shouldn't care about yahoos having done next to no due diligence, looking at a rev multiple and saying: undeserved. ISRG pinballed wildly for 2-3 yrs in its early days as a public co.